Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas explains the promising role of CAR-T cell therapies in lymphoma patients.
Author: Editor
Andre Goy, MD, Chairman and Director of the John Theurer Cancer Center (JTCC) at Hackensack University Medical Center and Chief of the Division of Lymphomas shares the exciting new data in lymphoma involving novel therapy for patients.
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center shares the important role biomarkers have in the treatment of pancreatic cancer patients.
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center describes the outcomes from the POLO study in pancreatic cancer and the importance of it.
Talia Golan, MD, Head of Sheba Pancreatic Cancer Center explains the potential of the POLO trial maintenance with olaparib in metastatic pancreatic cancer.
Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the next phase of hepatocellular carcinoma (HCC) management and the research that is included.
Daneng Li, MD, Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research, Liver Program Disease Team Lead, City of Hope offers the next steps if a hepatocellular carcinoma (HCC) patient fails 1st line therapy.
Richard S. Finn MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California offers his opinion on the role of immuno-oncology (I-O) in the management of hepatocellular carcinoma (HCC).
Richard S. Finn, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, Geffen School of Medicine, University of California explains the outcomes of hepatocellular carcinoma (HCC) in KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line HCC.
What therapy should we use for DLBCL in 2016
CLL and Non-Hodgkin Lymphoma, What new drugs are on the horizon and why are they exciting
CLL, What is the significance of IGHV mutations and how are they assessed
What is the Role of Maintenance Therapy and What do you do After
CLL and non-hodgkin lymphoma, What are the risks and benefits of both ibrutinib and Idelalisib
Not Your Fathers CLL with Dr. John Pagel
CLL, Is there a role still for chemo AND who should get chemo
CLL, FCR vs BR Is One Better
Chronic Lymphocytic Leukemia Non-Hodgkin Lymphoma Should all HL patients be treated the same
Are vaccines dead in lymphoma and CLL
Are all DLBCL made equally
GRACEcast-133_Breast_Elderly Breast Cancer Part 4 Advanced and Functional Assessment of Patients
GRACEcast-132_Breast_Elderly Breast Cancer Part 3 Surgery and the Value of Adjuvant Therapy
GRACEcast-130_Breast_Elderly Breast Cancer Part 2 Prevention Screening and Goals of Treatment
GRACEcast-128_Breast_Older Women with Breast Cancer Part 1 Defining Population Trends by Age.mp4
What To Discuss With Your Healthcare Team – a Diagnosis of Triple Negative Breast Cancer – Litton
What makes a triple negative breast cancer negative Reis Filho
Review of Recent Progress in Immunotherapy in Triple Negative Breast Cancer Schmid
Current Standard of Care in Triple Negative Breast Cancer – Yardley
Combination therapy IO Chemo in Triple Negative Breast Cancer Schmid
BRCA Mutations What does it Mean When Choosing My Treatment Litton
Philadelphia, PA (June 4, 2019) – Oncoceutics, Inc. announced a publication in the Journal for ImmunoTherapy of Cancerdemonstrating ONC201 immunostimulatory activity in advanced cancer patients when given the recommended phase II dose (RP2D) of 625 mg orally every one week.  The publication, which describes a Phase I trial conducted by Mark Stein, MD, at the Rutgers Cancer Institute of New Jersey (CINJ) to evaluate weekly oral administration of the company’s lead compound ONC201, also confirmed previous studies, which demonstrated that the drug was well-tolerated. Weekly dosing stimulated intratumoral infiltration and activation of natural killer (NK) cells. The immune stimulatory effects that…
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions considers the future of artificial intelligence being used by physicians.
Bruce Feinberg DO, VP Chief Medical Officer, Cardinal Health Specialty Solutions expresses some concerns surrounding artificial intelligence.
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions comments on how artificial intelligence may evolve into a necessary decision-making tool for physicians.
Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions discusses how artificial intelligence can increase efficiency and be more beneficial to physicians in the short term.
Bruce Feinberg DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions showcases real-world examples of artificial intelligence being used by physicians.
Bruce Feinberg, DO, VP, Chief Medical Officer, Cardinal Health Specialty Solutions explains the misunderstanding and complexity of artificial intelligence and how it can be used as a healthcare tool.
ASCO 2018 – Tarceva or Tarceva with Avastin as 1st Line for EGFR Pos. NSCLC vs. Tagrisso or Vizimpro
ASCO 2018: Combining Metformin with Standard EGFR Therapy
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center shares the next step for hepatocellular carcinoma (HCC) patient if the 1st line therapy fails.
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center explains the role of immuno-oncology (I-O) in the management of hepatocellular carcinoma (HCC) with the recent data provided.
Imane El Dika, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center discusses the outcomes of KEYNOTE-240 which compares pembrolizumab versus placebo in 1st line hepatocellular carcinoma (HCC).
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists explains the results from the SOPHIA trial, a phase III study of chemotherapy plus margetuximab or trastuzumab in HER+ metastatic breast cancer.
Neelima Denduluri MD, Associate Professor, US Oncology Research, Virginia Cancer Specialists shares the results of the phase III EMBARCA trial that compares the efficacy and safety of talazoparib (TALA) to PCT (capecitabine, eribulin, gemcitabine, vinorelbine) in HER2-metastatic breast cancer patients.
Debu Tripathy, MD, Professor and Chair, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center shares the results of ImPassion130, a phase III study adding atezolizumab to the 1st line chemotherapy with nab-paclitaxel in patients with PD-L1 positive metastatic triple-negative breast cancer (TNBC).
Neelima Denduluri MD, Associate Chair, US Oncology Research, Virginia Cancer Specialists explains the MONALESSA-7 trial outcomes in premenopausal metastatic breast cancer.
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on how myelodysplastic syndrome (MDS) patients who are ineligible for transplants can be managed.
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School discusses the recent wave of approvals in AML and how it has changed treatment planning for patients.
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School comments on the importance of the updated data on gilteritinib in acute myeloid leukemia (AML).
Daniel DeAngelo MD, Institute Physician, Professor of Medicine at Harvard Medical School elaborates on the phase III study of uproleselan with chemotherapy in patients with relapsed acute myeloid leukemia (AML).